Biosimilar Newsletter Archive
-
12.07.23 -- FDA Warning Letters Dipped, But Don't Get Cozy
12/7/2023
12/07/23 Biosimilar Development Newsletter
-
11.30.23 -- Sandoz launches Hyrimoz (adalimumab) High-Concentration Formulation In Europe
11/30/2023
11/30/23 Biosimilar Development Newsletter
-
11.22.23 -- Preformulation Of Excipients In Biologics Development
11/22/2023
11/22/23 Biosimilar Development Newsletter
-
11.16.23 -- Understanding The FDA's Current Focus On REMS
11/16/2023
11/16/23 Biosimilar Development Newsletter
-
11.13.23 -- Strategies To Industrialize Lentivirus And AAV Processes
11/13/2023
11/13/23 Biosimilar Development Newsletter
-
11.09.23 -- Strategies For mAb And mAb Variant Chromatography Process Development
11/9/2023
11/09/23 Biosimilar Development Newsletter
-
11.09.23 -- Legal & IP Protection For New Biotechs
11/9/2023
11/09/23 Biosimilar Development Newsletter
-
11.06.23 -- Design A Successful Viral Clearance Study For Your Biologic
11/6/2023
11/06/23 Biosimilar Development Newsletter
-
11.02.23 -- FDA Updates Labeling Recommendations For Biosimilar Products
11/2/2023
11/02/23 Biosimilar Development Newsletter
-
10.26.23 -- 5 Best Practices For Responding To FDA Form 483 Inspection Observations
10/26/2023
10/26/23 Biosimilar Development Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more